- FY25 revenue surged 56% YoY to US$803.8M with FY26 guidance targeting US$950-970M (+19% growth)
- CMS reimbursement for Gozellix effective October 2025 unlocks major US market expansion opportunity
- TLX101-Px (brain cancer imaging agent) submitted to EU in February 2026, representing next commercialization milestone
- Adjusted EBITDA reached US$39.5M in FY25, demonstrating path to sustained profitability
- Positioned against competitors with 70-80% market share (Lantheus PYLARIFY), but growing addressable market provides multiple expansion paths
Telix Pharmaceuticals (ASX:TLX) operates at the intersection of two major healthcare megatrends: precision medicine and oncology diagnostics. The…
